Xenetic Biosciences, Inc. financial data

Symbol
XBIO on Nasdaq
Location
Framingham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 629% % -21%
Debt-to-equity 18% % 46%
Return On Equity -65% % -31%
Return On Assets -55% % -24%
Operating Margin -116% % 33%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,291,056 shares 49%
Common Stock, Shares, Outstanding 1,542,139 shares 0%
Entity Public Float $5,301,818 USD 5.5%
Common Stock, Value, Issued $1,545 USD 0%
Weighted Average Number of Shares Outstanding, Basic 1,542,139 shares 0.03%
Weighted Average Number of Shares Outstanding, Diluted 1,542,139 shares 0.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,858,935 USD 13%
Research and Development Expense $3,334,323 USD 3.5%
General and Administrative Expense $2,835,312 USD -23%
Operating Income (Loss) $3,310,700 USD 24%
Nonoperating Income (Expense) $154,395 USD -46%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $3,156,305 USD 23%
Earnings Per Share, Basic -2 USD/shares 23%
Earnings Per Share, Diluted -2 USD/shares 23%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $5,067,960 USD -28%
Other Assets, Noncurrent $0 USD -100%
Assets $5,067,960 USD -37%
Accounts Payable, Current $578,250 USD 138%
Employee-related Liabilities, Current $243,396 USD 12%
Accrued Liabilities, Current $610,648 USD 7.4%
Liabilities, Current $1,111,775 USD 10%
Liabilities $1,111,775 USD 10%
Accumulated Other Comprehensive Income (Loss), Net of Tax $253,734 USD 0%
Retained Earnings (Accumulated Deficit) $199,296,255 USD -1.6%
Stockholders' Equity Attributable to Parent $3,956,185 USD -44%
Liabilities and Equity $5,067,960 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,001,892 USD 14%
Common Stock, Shares Authorized 10,000,000 shares 0%
Common Stock, Shares, Issued 1,544,840 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,121,599 USD -40%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $41,700,000 USD 2.7%
Deferred Tax Assets, Gross $41,129,537 USD 3.6%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $208,276,537 USD 0.04%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $104,000 USD -29%